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Abstract  
In the March 1st issue of Cancer Research, we identified the Wnt receptor Fzd7 as an attractive 
therapeutic target for the treatment of gastric cancer. In summary, we showed that pharmacological 
inhibition of Wnt receptors, or genetic deletion of Fzd7, blocks the initiation and growth of gastric 
tumours. Inhibiting Fzd receptors, specifically Fzd7, inhibits the growth of gastric cancer cells even in the 
presence of Adenomatous polyposis coli (Apc) mutation. Apc is located in the cytoplasm downstream of 
Fzd7 in the Wnt sig ali g cascade a d APC utatio s acti ate W t/β-catenin signaling, therefore this 
result seems counterintuitive. Here, we analyze this result in greater detail in the context of current 
knowledge of Wnt signaling, and discuss the wider implications of this aspect of Wnt signaling in other 
cancers. 
 
Regulation of Wnt signaling intracellularly and at the plasma membrane 
The Wnt signaling pathway regulates many cell functions, including proliferation, migration, apoptosis 
and differentiation [1]. It is essential during embryonic development and also in homeostasis of several 
adult tissues including the GI tract [2, 3], liver, breast and skin [1], and is deregulated in many cancers 
including colon, gastric, breast and liver [4]. Wnt ligands are secreted glycoproteins which bind to a U  
shaped pocket in the dimer of Fzd receptors via a lipid modification of palmitoleic acid to form a 
receptor complex with co-receptors, including Lrp5/6 and Lgr4/5 [1]. This complex interacts with 
co po e ts of a c toplas ic dest uctio  co ple  hich co tai s Gsk3, Axin, Ck1 and Apc, to form a 
large signalosome [1]. In the absence of a Wnt ligand, e l  t a slated β-catenin proteins are bound 
and phosphorylated by the destruction complex. However, in the presence of Wnt/Fzd binding, 
signalosome assembly disrupts this process a d β-catenin is free to accumulate, translocate into the 
nucleus and associate with transcription factors Tcf/Lef to regulate target gene transcription [1] (Fig. 
1A). 
 
Nuclea  β-catenin, a hallmark of active Wnt signaling [1], is observed in ~30% of human gastric tumours 
[5]. Next generation sequencing has revealed that Wnt signaling is deregulated in gastric tumours at 
several points in the pathway including the ligand, receptors and intracellular transduction components 
[6, 7]. In addition to mutations, epigenetic changes are also observed in gastric tumours to Wnt 
inhibitors such as sFRP (binds directly to Wnt ligands) and Dkk1 (binds to and inhibits Lrp5/6 receptors), 
resulting in activation of Wnt signaling at the level of the receptor/ligand [1]. Indeed, RNF43, an E3 
ubiquitin ligase that turns over Fzd on the cell surface [8] is mutated in ~18% of human gastric tumours, 
whilst many Wnt ligands are overexpressed [7]. This is around the same frequency (~18%) observed for 
APC mutations in GC, ~37% of which also contain an RNF43 mutation, indicating compound activation of 
Wnt signaling in the same tumour [7]. This observation that Wnt signaling is regulated intracellularly and 
at the plasma membrane is consistent with our experimental data in which we could inhibit the growth 
of Apc mutant gastric tumours by deleting Fzd7 and prompts a frequently asked question when 
p ese ti g this o k, ho  ca  a cell ith mutant Apc respond to inhibition of a Fzd receptor 
upst ea ? .   
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Heterogenous Wnt signaling regulates distinct cell functions in a tumour 
To answer this question, we first need to highlight that Wnt signaling is not a binary system whereby the 
pathway is on or off, but rather is highly regulated in a compound fashion to provide spatial and 
temporal variation depending on multiple environmental factors [9]. This was first demonstrated by 
Thomas Brabletz in 1998, who showed heterogenous expression of uclea  β-catenin (a surrogate 
marker of active Wnt signaling) within human CRCs, despite all tumour cells harboring APC mutation 
[10] (Fig. 1B). Furthermore, Wnt signaling is promoted by macrophage-derived TNF-α [11] and H. pylori 
infection can activate the Wnt pathway via Fzd7 [12], highlighting a role for the microenvironment for 
variable Wnt activity in tumours.  This indicates that additional factors can regulate Wnt signal strength 
even in APC mutant cells. This can occur because the APC gene is not deleted but truncated and mutant 
APC is still transcribed and translated into a protein which is able to partially function in the destruction 
complex and respond to WNT ligands, albeit at a reduced level [13, 14]. Indeed, Wnt3 secretion 
maintains high Wnt signaling in APC mutant colon cancer cells [14], whilst APC is methylated, and 
subsequently inhibited further during tumour progression in colon tumours, highlighting variable Wnt 
activity as a feature of colon tumours [15]. This explains why APC mutant cells are sensitive to Fzd 
inhibition in our work, but what is the function of this variable Wnt signal? 
 
Approximately 37% of APC mutant gastric tumours also contain RNF43 mutations, indicating compound 
activation of Wnt signaling in the same tumour [3]. However, only 5.5% of colon tumours have APC and 
RNF43 mutations, suggesting that GC and CRC preferentially select different mechanisms of optimal, 
just ight , le els of W t sig ali g e ui ed fo  tumour growth and progression. The just right  model of 
Wnt signaling proposes APC mutations are selected for sub-maximal levels of Wnt signaling to provide a 
Wnt signal that is sufficient to transform cells, but not excessive and cytotoxic [16]. Experimental 
evidence from in vivo data helped confirm these models. For instance, the Apc
1322T/+
 mouse model 
etai s a si gle β-catenin binding domain in the mutant Apc1322T allele, which develops more severe 
intestinal tumours, but with lower levels of Wnt signaling compared to other Apc mutant models that 
lack β-catenin binding capacity [17]. Additionally, we have previously shown that intestinal 
tumourigenesis is reduced in Cited1
+/-
; Apc
Min/+
 mice due to very high, cytotoxic Wnt signaling [18]. These 
data correlate with observations of improved clinical outcomes after relapse for molecular subtypes of 
colon cancer which display high Wnt signaling [19]. 
 
Notably, a common theme is emerging for epithelial tumours which indicates that cancer cells harbor 
mutations of intracellular components of the Wnt pathway with additional mutations or epigenetic 
modifications at the level of the receptor/ligand to permit further regulation of Wnt signaling (ligand 
and receptor overexpression) (Fig. 2). The net result, at least in colon cancer, appears to be to constrain 
Wnt signaling ithi  a  opti al just ight  spectrum in the cancer cells, with bursts of intense signaling 
in a context dependent manner, for example at the invasive front of colon tumours (Fig 1). Given the 
context-dependent manner of Wnt signaling during development [9] this is perhaps not surprising. 
Importantly, despite multiple mutations within a cancer cell, correcting or inhibiting one gene in the 
Wnt pathway that is altered in cancer can potently inhibit tumour growth. This has important 
implications for cancer therapy. For example, restoring the function of APC in APC-mutant colon cancer 
cells inhibits tumour growth [20, 21], implying that mutation of APC is not just an initiating event in the 
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genesis of colon cancer but provides the genetic platform that sustains the tumour. Restoring wild-type 
APC removes that platform. Furthermore, restoring sFRP for example [22], or blocking Fzd7 signalling in 
APC mutant colon cancer cells [23] or gastric cancer cells [7], inhibits Wnt signaling and tumour growth, 
again, despite the tumour cells harboring many other mutations, i plicati g the i po ta ce of just 
ight  W t sig ali g. Notably, Wnt signaling can be further stimulated by inhibiting GSK3 or addition of 
WNT3A in APC mutant colon cancer cells [14, 24], which suggests potential regulation also at the 
destruction complex even if APC is mutated [24]. Furthermore, other members of the Fzd family of Wnt 
receptors have been implicated in many cancer types, including GC in which we observed that Fzd2 and 
Fzd6 were also upregulated in human GC cells [7], and therefore future research will help determine 
their functional roles.   
 
Another important function of variable levels of Wnt signaling in tumours is to regulate cancer stem cell 
(CSC) activity. Stromal myofibroblast-derived hepatocyte growth factor (HGF) can increase Wnt signaling 
in APC mutant colon cancer cells and endow them with CSC features of self-renewal [25]. CSCs also 
display invasive and metastatic features, with CD44+ CSCs frequently observed at the invasive front of 
gastric tumours [26]. There are considerable similarities between migrating cells in the developing 
embryo and metastasizing tumour cells. During gastrulation populations of cells undergo an epithelial to 
mesenchymal transition (EMT) and become motile to set up the complex tissue patterning of the 
developing embryo [27]. Nuclea  β-catenin is observed in migrating cells during early gastrulation, and 
β-catenin deficient mouse embryos fail to develop mesoderm [28]. Areas of increased Wnt signaling 
activity are often observed at the leading edge of tumours as can be seen in Figure 1 which shows 
i c eased e p essio  of β-catenin at the invasive front of a human colon tumour. These data suggest an 
environmental regulation of Wnt signaling in APC mutant colon cells is high-jacking a developmental 
process to promote tumour invasion/metastasis.  
 
Non-canonical PCP Wnt signaling is also critical for correct polarization of tissues and cell migration 
during gastrulation and is implicated in metastasis of several cancer types [29]. During neural crest 
migration, the small GTPase, and PCP signaling component, RhoA, acts to promote the retraction of cell 
protrusions [30]. In colon tumours, RhoA levels are reduced in metastatic sites compared to the primary 
tumour, and inactivation of RhoA increases canonical Wnt signaling to promote metastasis [31]. 
Furthermore, RhoA mutations are recurrent in genomically stable gastric tumours, suggesting they 
contribute to the invasive phenotype of diffuse gastric tumours [32].   
 
The processes of EMT and MET are also regulated by Wnt signaling, with several Wnts and Fzds now 
implicated in both EMT and MET including FZD7 [24, 33, 34]. Wnt signaling can promote invasion of 
cancer cells by regulating genes involved in cell adhesion, including Eph/Ephrins and E-cadherin [35]. 
Several matrix metalloproteinase (MMP) genes are also regulated by Wnt signaling in numerous cancers 
[36, 37], including gastric cancer [38], which degrade proteins in the surrounding stroma including 
collagen, gelatin, fibronectin and laminin, to provide a permissive microenvironment to allow invading 
cells to migrate. These data illustrate that the heterogenous activation of Wnt signaling in tumours is 
regulated by deregulation of the pathway, at the level of the ligand/receptor, which is supported by 
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RNASeq data (Fig. 2), and that different levels of Wnt activity regulate different cellular functions 
including stemness, EMT/MET and invasion during cancer progression.  
 
It is worth mentioning that many right-sided CRCs, which are associated with poor prognosis, are not 
mutant for APC and instead have mutations to RNF43 (cbioportal website) or methylation of Dkk1 [39] 
or sFRP [22], which facilitate elevated Wnt signaling (Fig. 2). In the absence of an APC mutation, CRC 
cancers can acquire gain-of-function CTNNB1 mutations that e de  β-catenin resistant to proteasomal 
degradation [40]. However, the selection bias towards APC in preference to CTNNB1 mutations has been 
shown to reflect the abundance of colonic E-cadherin that can sequester uta t β-catenin, acting as a 
sink to prevent transformation [41]. Hepatocellular carcinoma (HCC) is the most common form of liver 
cancer, around 50% of which harbor similar mutations in the CTNNB1 gene [42]. Similar to CRC and GC, 
HCC also exhibit deregulation of Wnt components at the receptor/ligand level, including overexpression 
of Wnt ligands and FZD receptors, and down-regulation of sFRPs [4]. Here too CTNNB1 mutation alone 
does not cause liver cancer in mouse models but instead provides a platform in which tumour 
progression is accelerated in association with other factors including Kras [43] and Lkb1 [44].  
 
Context specificity of Apc mutant cells to modulation of Wnt signaling  
Despite compelling evidence outlined above that demonstrates Wnt signaling can be further regulated 
at the level of the receptor in Apc mutant cells, recent work indicates this phenomenon is context 
dependent. Intestinal stem cells (ISCs) are continuously engaged in a stochastic competitive process 
termed neutral-drift [45]. This process is neutral as all ISCs have equal probability of replacing their 
neighbour or being replaced. However, oncogenic mutations, in genes such as Apc, bias this competition 
in favour of Apc mutant cells such that they displace all wild-type ISCs cells from the niche and the crypt 
will become clonal with Apc-mutant progeny [46]. Indeed, lowering the overall level of Wnt ligands in an 
Apc mutant background further exacerbates the decreased fitness of non-mutant ISCs, allowing for the 
rapid clonality of Apc mutant ISCs, which accelerates intestinal tumour formation [47]. Similar size 
changes to the ISC pool and rate of clonality were observed following selective inhibition of a single 
binding site for R-Spondin, which is required to potentiate Wnt signaling [48], indicating that 
fluctuations in Wnt signaling can impact the dynamics of ISCs and in turn influence tumour initiation.  
 
Some important insight has been gained recently into how APC mutant cells activate Wnt signaling. Wnt 
pathway activation was observed in APC mutant CRC cells which were unable to secrete Wnt ligands due 
to a mutation in PORCN (or treatment with PORCN inhibitor), and this activation was partially inhibited 
(~50%) in LRP6 mutant cells [49]. This response was not observed in CTNNB1 mutant CRC cells 
suggesting a specific role for mutant APC. Further analysis revealed that APC knockdown, but not APC2 
knockdown, triggered the assembly of the Wnt signalasome and clathrin mediated endocytosis to 
activate Wnt signaling in CRC cells. However, as we observed that APC mutant GC cells can respond to 
PORCN inhibitors [7], further research will be needed to determine if similar mechanisms exist in other 
cancer types.   
The recent molecular subtyping of multiple cancers has greatly enhanced our understanding of cancer 
genetics and disease stratification. Using a network-based approach, four consensus molecular subtypes 
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(CMS) of CRC were recently identified, of which CMS2 and CMS3 display the highest levels of Wnt 
signaling and superior patient outcome. Interestingly, approximately 66% of CMS4 CRCs have mutations 
to APC and also display high stromal infiltrate, TGF signaling and have the poorest survival [19]. 
However, poor clinical prognosis in CMS4 CRC subtypes is associated with receptor-mediated Wnt 
activation, whereas oncogenic Wnt activation (mutant APC) is associated with improved patient 
outcome and CMS2 [50]. Collectively, this indicates disease/tumour progression needs to be considered 
when selecting the type (agonist vs antagonist) of WNT therapeutic in CRC, as increasing Wnt activity 
could be beneficial to patients with CMS4 tumours.  
 
Summary 
There is now substantial evidence that targeting the Wnt pathway at the level of the receptor/ligand is 
an attractive therapeutic strategy for inhibiting tumour growth, and potentially metastasis. Indeed, 
several drugs targeting the Wnt pathway at the level of the ligand/receptor are currently in clinical trials, 
some of which focus on metastatic disease. The monoclonal antibody Vantictumab (OMP-18R5 
Oncomed/Bayer) binds to Fzd1, 2, 5, 7 and 8, is in Phase Ib clinical trials for pancreatic cancer, 
metastatic breast cancer and non-small cell lung cancer [51]. Porcupine inhibitors, which prevent the 
secretion of all Wnt ligands, are also in phase I clinical trials for advanced solid tumours (NCT01351103). 
We demonstrated Vantictumab was able to inhibit the growth of the growth of gastric tumours, with 
and without Apc mutations [7], suggesting this approach could also benefit gastric cancer patients. 
Further research in pre-clinical models is required to determine the therapeutic potential of targeting 
the Wnt pathway at the level of the ligand/receptor for metastatic disease, but the growing molecular 
evidence suggests this is an attractive strategy, and current clinical trials will help resolve this in the 
future, along with continued drug discovery programmes to target Wnt signaling, and combination 
therapies to optimize treatment.  
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Figure Legends 
 
Figure 1. Wnt signalling with mutant Apc.  A. The le els of c toplas ic β-catenin are regulated by the 
degradation complex which is inhibited when Wnt signalling is active (left hand panel). In Apc mutant 
cells it is often misconceived that Apc is completely deleted and therefore the degradation complex is 
non-functional and Wnt signalling cannot be regulated upstream of the degradation complex at the level 
of the receptor/ligand (illustration faded out, central panel). However mutant Apc is transcribed and 
translated resulting in a compromised, yet fu ctio al, β-catenin degradation complex which explains 
how upstream factors including sFRP, Dkk and Fzd inhibitors can still modulate Wnt signal activity (right 
hand panel). B. I u ohistoche ist  fo  β-catenin in a human colorectal carcinoma showing increased 
nuclear localisation, as a surrogate marker of active Wnt, in the invasive front compared to the tumour 
center (from Brabletz et al. Pathol Res Pract. 1998;194:701-4). 
 
Figure 2. Alteration of Wnt pathway components in epithelial cancers. Analysis of selected datasets 
from The Cancer Genome Atlas (TCGA) for mutations, amplifications and deletions of either intracellular 
(APC, β-catenin, Axin2 and Dvl) or receptor (e.g. WNTs, FZDs, RNF43, sFRP) pathway components. 
Relative frequency of genetic alterations shown as percentages. NSCLC = Non small cell lung cancer; CRC 
= Colorectal cancer; GBM = Glioblastoma. This figure was generated using data available at 
www.cbioportal.org. 
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